Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Important genomic factors for SM progression

Brian Walker • 13 Sep 2019
IMW 2019
Multiple Myeloma

Brian Walker, PhD, University of Arkansas for Medical Sciences, Little Rock, AR, speaking from the International Myeloma Workshop (IMW) 2019, held in Boston, MA, discusses the primary genomic factors that contribute to the progression of smoldering myeloma (SM).

More from Brian Walker

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
An update on the genomic landscape of MM 2:00
An update on the genomic landscape of MM
Brian Walker • 15 Sep 2019
Non-coding mutations impact gene expression in myeloma 0:42
Non-coding mutations impact gene expression in myeloma
Brian Walker • 13 Sep 2019
Re-evaluating the role of epigenetics in multiple myeloma 12:00
Re-evaluating the role of epigenetics in multiple myeloma
Brian Walker et al. • 18 Oct 2017

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals